Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Elan Corporation
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.
Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.
After years of setbacks, the company will launch its device in Europe as a bridge to transplant in heart failure patents.
Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs.
- Other Names / Subsidiaries
- Onclave Therapeutics Limited